Table 1.
Disorders | miRNA | Delivery system | Regulation | Gene of interest | In vitro/In vivo | Outcome summary | Reference |
---|---|---|---|---|---|---|---|
Osteoporosis (OP) | mmu-miR-17/20a-5p | Lipofectamine 2000 complexes | ↑ | RANKL | MC3T3-E1, C57BL/6 mice | 窗体顶端 | (Shi et al., 2014) |
Attenuated Dexamethasone- induced osteoclast differentiation and function | |||||||
mmu-miR-29a-3p | Lentivirus | ↑ | Dkk-1 | SD rat | Protects against GC-induced bone loss and fragility | (Wang et al., 2013b) | |
mmu-miR-34a-5p | X-tremeGENE Transfection Reagent | ↓ | CDK4, CDK6, | C57BL/6 mice | 窗体顶端 | (Kang et al., 2016a) | |
Cyclin D1 | Impaired BMSC osteogenic differentiation and aggravated osteoporsis | ||||||
mmu-miR-140/214-3p | Baculovirus vectors | ↓ | JAG1, Tmem119, ATF-4, Osterix | SD rat | Promoted bone formation and mitigated excessive bone resorption | (Li et al., 2016c) | |
mmu-miR-34a-5p | Lipofectamine RNAi MAX |
↑ | Tgif2 | C57BL/6J mice | Elevated bone resorption and reduced bone mass | (Krzeszinski et al., 2014) | |
Bone defect | hsa-miR-21-5p | Chitosan/hyaluronic acid nanoparticles | ↑ | Runx2 | hBMSC | Significantly improved osteogenesis | (Schoolmeesters et al., 2009, Wang et al., 2015b) |
mmu-miR-26a-5p | Lipofectamine 2000 complexes | ↑ | OCN, COL1 | 窗体顶端 | Satisfactory bone repair in tibial defect | (Wang et al., 2015a) | |
Rabbit ASC | |||||||
mmu-miR-29a-3p | Gelatin solutions | ↓ | IGF1, tfgb1 | MC3T3-E1 | Significantly enhanced ECM deposition | (James et al., 2014) | |
mmu-miR-31-5p | Lipofectamine 2000 complexes | ↓ | Runx2, Satb2 | SD rat | Good biocompatibility and bone regeneration | (Deng et al., 2014, Deng et al., 2013) | |
mmu-miR-138-5p | Lipofectamine 2000 complexes | ↓ | Runx2 | C57BL/6 mice, | 窗体顶端 | (Yan et al., 2014) | |
rat BMSC | Massive bone with good vascularization | ||||||
hsa-miR-148b-3p | Silver nanoparticle complexes | ↑ | Runx2, OCN | hASC | Promoted osteogenic differentiation | (Qureshi et al., 2013) | |
Primary bone tumor | hsa-miR-20a-5p | Lipofectamine 2000 complexes | ↓ | EGR | MG63, SaSO2, SW1353 | Inhibited cell proliferation and cycle | (Zhou et al., 2015) |
hsa-miR-22-3p | Lipofectamine 2000 complexes | ↑ | ACLY | SaSO2, PC3, Hela, A549 | Inhibited growth and metastasis of various tumors | (Xin et al., 2016) | |
hsa-miR-26a-5p | Lentivirus vector | ↑ | Jagged1 | MG63, SaSO2, 143B, U2OS, BALA/c nude mice | Suppressed CSCs phenotype and tumor growth | (Lu et al., 2016) | |
hsa-miR-106a-5p | Lipofectamine 2000 complexes | ↑ | HMGA2 | MG63, SaSO2, HOS, U2OS | Inhibited proliferation, migration and invasion | (He et al., 2016) | |
hsa-miR-106b-5p | FuGENE HD transfection agent | ↑ | RANKL, IL-8, MMP2, TWIST | mice BMM, GCTSC, OVX mouse | Inhibited bone resorption and osteolysis | (Wang et al., 2015c) | |
hsa-miR-126-5p | FuGENE HD transfection agent | ↑ | MMP-13, PTHrP | mice BMM, GCTSC | Suppression of osteoclast differentiation and bone resorption | (Wu et al., 2014a, Zhou et al., 2014) | |
hsa-miR-126-5p | Lipofectamine 2000 complexes | ↑ | Sirt 1 | SaSO2 | 窗体顶端 | (Shi et al., 2015, Xu et al., 2013) | |
inhibited proliferation, migration, invasion and epithelial-mesenchymal transition | |||||||
hsa-miR-204-5p | |||||||
hsa-miR-145-5p | Lipofectamine 3000 complexes | ↓ | FLI-1 | MG63, SaSO2 | Inhibited tumor progression | (Wu et al., 2016b) | |
hsa-miR-409-3p | Lipofectamine 2000 complexes | ↑ | Catenin-δ1 | U2OS | Inhibited migration and invasion | (Wu et al., 2016a) | |
hsa-miR-646 | Lipofectamine 2000 complexes | ↑ | FGF-2 | MG63, SaSO2, HOS, U2OS | Suppression of metastasis | (Sun et al., 2015) | |
Secondary metastasis | hsa-miR-34a-5p | Lentivirus vector | ↑ | TCF-7 | PC3, RasB1 | Inhibited bone metastasis of Ras-activated PC | (Chen et al., 2015) |
hsa-miR-335-5p, | Lentivirus vector | ↑ | eNOS | PC3 | Inhibited bone metastasis of PC | (Fu et al., 2015) | |
hsa-miR-543 | |||||||
Osteoarthritis (OA) | hsa-miR-23a-3p, | Lipofectamine 2000 complexes | ↓ | Samd3 | SW1353 | Promoted type II collagen and aggrecan expression | (Kang et al., 2016b, Li et al., 2015) |
hsa-miR-16-5p | |||||||
hsa-miR-139-5p | Lipofectamine RNAi MAX |
↓ | EIF4G2, IGF1R | CHON-001 | Protective effects on chondrocyte proliferation and migration | (Hu et al., 2016) | |
hsa-miR-142-3p | Lipofectamine 2000 complexes | ↑ | HMGB-1 | C57BL/6 mice | Suppressed inflammation and chondrocyte apoptosis | (Wang et al., 2016b) | |
mmu-miR-210-5p | Geneporter 2 Transfection Reagent |
↑ | DR6 | SD rat | Suppressed inflammation and chondrocyte apoptosis | (Zhang et al., 2015a) | |
hsa-miR-365a-3p | Lipofectamine 2000 complexes | ↓ | HDAC4 | Primary chondrocyte from OA patient | Inhibited expression of MMP13 and Col X | (Yang et al., 2016) |